Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FHD-286 (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Foghorn Therapeutics

    • Most Recent Events

    • 16 Dec 2024 According to a Foghorn Therapeutics media release, company expects to report the results at a medical conference in 2025.
    • 16 Dec 2024 Status changed from recruiting to discontinued because the observed response rate did not meet the threshold to continue development by Foghorn alone as per a Foghorn Therapeutics media release.
    • 04 Nov 2024 According to a Foghorn Therapeutics media release, topline safety, tolerability, initial efficacy, and PK/PD data expected by year-end 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top